Skip to main content
Healthy AdultDiagnostics and screeningHealthy volunteersHeart and circulationDrugEarly Phase 1

What this study is

The goal of this clinical trial is to determine the biodistribution, safety, and calculate the radiation dosimetry of the novel atherosclerotic PET imaging radiotracer, 64Cu-NODAGA-CANF, in normal healthy adult volunteers.

Participants will receive a single intravenous administration of 64Cu-NODAGA-CANF and then undergo PET-CT imaging at various time points following injection. Safety will be assessed through evaluation of vital signs, clinical laboratory tests, physical examination, and electrocardiograms (EKGs). Telephone follow-up will occur 2-3 days after discharge.

What's being tested

  • 64Cu-NODAGA-CANF

    Intervention · DRUG

    Single intravenous (IV) injection of less than 4 mCi of 64Cu-NODAGA-CANF followed by PET-CT imaging at 3 or 4 time points up to 48 hours post-injection (30-60 minutes, 2-6 hours, 18-24 hours and 40-48 hours).

Study details

Official title
PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Volunteer - Dosimetry Study)
Sponsor
Washington University School of Medicine
Conditions
Healthy Adult · Healthy
Enrolling
8 people
Starts
2026-08-19
Est. completion
2027-05-31
Design
Open-label, single group, Early Phase 1
Record
View on ClinicalTrials.gov ↗